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Abstract
Background: Klebsiella species are among the most common causes of bloodstream infection (BSI). However, few
studies have evaluated their epidemiology in non-selected populations. The objective was to define the incidence
of, risk factors for, and outcomes from Klebsiella species BSI among residents of the western interior of British
Columbia, Canada.
Methods: Population-based surveillance was conducted between April 1, 2010 and March 31, 2017.
Results: 151 episodes were identified for an incidence of 12.1 per 100,000 population per year; the incidences of K.
pneumoniae and K. oxytoca were 9.1 and 2.9 per 100,000 per year, respectively. Overall 24 (16%) were hospital-onset, 90
(60%) were healthcare-associated, and 37 (25%) were community-associated. The median patient age was 71.4
(interquartile range, 58.8–80.9) years and 88 (58%) cases were males. Episodes were uncommon among patients aged
< 40 years old and no cases were observed among those aged < 10 years. A number of co-morbid medical illnesses
were identified as significant risks and included (incidence rate ratio; 95% confidence interval) cerebrovascular accident
(5.9; 3.3–9.9), renal disease 4.3; 2.5–7.0), cancer (3.8; 2.6–5.5), congestive heart failure (3.5; 1.6–6.6), dementia (2.9; 1.5–5.2),
diabetes mellitus (2.6; 1.7–3.9), and chronic obstructive pulmonary disease (2.3; 1.5–3.5). Of the 141 (93%) patients
admitted to hospital, the median hospital length stay was 8 days (interquartile range, 4–17). The in-hospital and 30-day
all cause case-fatality rates were 24/141 (17%) and 27/151 (18%), respectively.
Conclusions: Klebsiella species BSI is associated with a significant burden of illness particularly among those with
chronic co-morbid illnesses.
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Background
The Klebsiella genus, which including the species K.
pneumoniae, (including subspecies pneumoniae and ozo-
nae), K. oxytoca, and K. variicola are important human
pathogens. Klebsiella pneumoniae is second to Escheri-
chia coli as the most frequent cause of Gram-negative
bloodstream infections (BSI) in both hospital and com-
munity settings [1]. Klebsiella pneumoniae is an
important cause of pneumonia, urinary tract infections,
septicemia, and intra-abdominal infections [2, 3]. Klebsi-
ella pneumoniae has become increasingly important in
recent years, as invasive hypermucoid strains have been
linked to pyogenic liver abscesses most notably in Taiwan
and Korea [4, 5], and there has been an upswing in ex-
tended spectrum-β-lactamase (ESBL) producing strains
worldwide [6–8]. Species other than K. pneumoniae are
overall less frequent and have been associated with condi-
tions including BSIs, urinary tract infections, soft tissue in-
fections, and respiratory tract infections [9–11].
Population-based studies minimize a number of im-
portant biases and have been recognized as optimal
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designs to evaluate the epidemiology of BSIs [12]. How-
ever, to our knowledge only three previous studies have
evaluated Klebsiella species BSI in non-selected popula-
tions [1, 13, 14]. Furthermore, only one of these has
quantified the risks for development of Klebsiella species
BSI related to specific co-morbid illnesses [1]. The ob-
jective of this study was to determine the incidence and
risk factors for acquiring Klebsiella species BSI among
residents of a non-selected Canadian population.
Methods
Study population & surveillance
Population surveillance was conducted in the western
interior region of British Columbia, Canada (2016 popu-
lation 182,422) as previously described [15]. The regional
microbiology laboratory at the Royal Inland Hospital in
Kamloops identified all residents in the selected area
with Klebsiella species BSI. A senior infectious disease
consultant (KBL) then performed a case-by-case chart
review to abstract clinical information. The Charlson
Comorbidity Index (CCI) was used to classify comorbid
illnesses [16]. This study was granted a waiver of individ-
ual informed consent by the Interior Health Research
Ethics Board (file 201,314,052-I).
Laboratory procedures and definitions
The BacT/Alert 3D System (bioMerieux, France) was used
for blood culturing. Draw of two sets of blood cultures
consisting of aerobic/anaerobic bottle pairs from different
sites was standard. Organisms were isolated and speciated
by examining lactose-fermenting mucoid colonies on
MacConkey agar plates. Oxidase tests and MALDI-TOF
were then used, along with Gram stain results, for species
identification. For the purposes of this study, K. pneumo-
niae included those identified as K. pneumoniae and K.
pneumoniae subspecies pneumoniae or ozonae.
Incident Klebsiella species BSI was established by the
first growth from one or more blood culture sets. Repeat
positive cultures within 30 days were deemed be of the
same episode. Those reoccurring within 30–365 days
were classified as incident if the index episode resolved
following treatment. Contaminants were excluded and
clinical significance and determinants were established
by a review of all information in the electronic health
record. Hospital-onset BSI were those where the inci-
dent blood culture was drawn 48 h or more and
community-onset BSI less than 48 h after acute care hos-
pital admission [17]. Community-onset BSIs were sub-
classified as either community- or healthcare-associated
using the Freidman et al definitions [18].
Statistical analysis
Stata version 15 (Stata Corp, College Station, TX) was
used for all analyses. Fisher’s exact test was used to
examine differences in proportions among categorical
data. Skewed continuously distributed variables were de-
scribed using medians with inter-quartile range (IQR)
and were compared using the Wilcoxon-Mann-Whitney
test. Incidence rates were expressed as annual rates per
100,000 resident population and calculated using census
data [19]. Risks were reported as incidence rate ratios
(IRR) with 95% confidence intervals (CI) and were calcu-
lated using as numerator and denominator the incidence
with and without a factor, respectively. Selected co-
morbid illnesses were assessed as risk factors for the de-
velopment of Klebsiella species BSI. Denominator data
was obtained from local sources [20, 21], provincial and
national surveys [22–28], and studies published else-
where [29]. P-values less than 0.05 were deemed to rep-
resent statistical significance.
Results
Incidence
During the seven years of surveillance, 153 incident BSI
isolates of Klebsiella species were identified. In two cases
infections had two different incident Klebsiella species
concomitantly isolated and these included one patient
with K. oxytoca and K. pneumoniae while another with
K. oxytoca and K. variicola co-infection. There were
therefore 151 incident Klebsiella species BSI episodes
among 139 regional residents for an overall annual inci-
dence rate of 12.1 per 100,000 population per year. The
incidence of K. pneumoniae and K. oxytoca were 9.1 and
2.9 per 100,000 population per year, respectively. The
remaining two incident isolates were K. variicola. Eleven
patients had a second and one patient had a third epi-
sode of Klebsiella species BSI during the surveillance
period. Twenty-four cases (16%) were hospital-onset, 90
(60%) were healthcare associated, and 37 (25%) were
community-associated.
The annual incidence varied during the study years as
shown in Fig. 1. The first five years of the study demon-
strated moderate year-to-year variability ranging from
6.8 to 11.7 per 100,000 annually but there was then a
marked increase during the fifth and six years of the
study (Fig. 1). Although both species increased in inci-
dence in the latter years of the study this was predomin-
antly related to K. pneumoniae BSI in the last study year.
Risk factors and predisposing conditions
The median patient age was 71.4 (IQR, 58.8–80.9) years
and 88 (58%) were males. No cases were observed among
those aged less than 10 years and the incidence increased
with older age as shown in Fig. 2. Males were at higher
risk but this was not statistically significant (14.0 vs. 10.1
per 100,000; IRR, 1.4; 95% CI, 1.0–1.9; p = 0.06).
The median CCI was 2 (IQR, 1–4). Twenty-eight
(19%) patients had a CCI of zero, and sixty-two (41%)
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had scores of 1–2, thirty-two (21%) 3–4, and twenty-
nine (19%) had five or more. A number of co-
morbidities were examined as risks for development of a
Klebsiella species BSI within the population and these
are shown in Table 1.
Clinical foci and microbiology
The most common focus of infection was intra-
abdominal or genitourinary as shown in Table 2. Al-
though K. pneumoniae was much more likely to be of
hospital-onset as compared with K. oxytoca BSI (23/113;
Fig. 1 Age and gender specific incidence of Klebsiella species bloodstream infection
Fig. 2 Incidence of Klebsiella species bloodstream infection over time (Kp = Klebsiella pneumoniae; Ko = Klebsiella oxytoca)
Reid et al. BMC Infectious Diseases         (2019) 19:1070 Page 3 of 7
20% vs. 1/35; 3%; relative risk 7.1; 95% confidence inter-
val 1.0–50.9; p = 0.016), otherwise the demographics and
clinical features were similar (Table 2). Although there
was a high rate of resistance to ampicillin, most isolates
overall were susceptible to ceftriaxone, ciprofloxacin,
gentamicin, and co-trimoxazole (Table 2). As compared
to K. pneumoniae, K. oxytoca had a significantly reduced
rate of susceptibility to cefazolin (Table 2).
Hospital admission and outcome
One hundred and forty-one (93%) patients were admit-
ted to hospital for a median hospital length stay of 8
(IQR, 4–17) days. The in-hospital and 30-day all cause
case-fatality rates were 24/141 (17%) and 27/151 (18%),
respectively. The 30-day all cause case-fatality rates were
20% (23/113) and 9% (3/35; p = 0.1) for K. pneumoniae
and K. oxytoca, respectively.
Discussion
In this study, we observed that Klebsiella species are fre-
quent causes of BSI. The incidence rate of Klebsiella
species BSI was 12.0/100,000, and a number of co-
morbid medical conditions were associated with signifi-
cantly increased risk. Furthermore, one in five patients
suffering from Klebsiella species BSI died within 30 days
of diagnosis. Klebsiella species BSI cause a significant
burden of illness in our population.
To our knowledge, there are only three previous
population-based studies published for comparison [1,
13, 14]. Meatherall et al reported on 640 episodes in
the Calgary area of Canada during the years 2000 to
2007 and found an incidence rate of for K. pneumo-
niae of 7.1/100,000 [1]. Pepin reported an incidence
of 18.7/100,000 in Sherbrooke, Canada, between the
years 1997 and 2007, with 411 episodes identified in
that time [14]. Finally, Al-Hasan reported 127 epi-
sodes in Olmsted County, Minnesota, between the
years 1998 and 2007, with an annual incidence rate of
11.7/100,000 for Klebsiella species BSI, and 9.7/100,
000 for K. pneumoniae specifically [13]. The cumula-
tive data from North American population-based
studies to date indicate that the incidence rate for
Klebsiella species BSI is comparable to our observed
rate of 12 per 100,000. Individual differences between
studies may potentially be explained in part by differ-
ences in demographics, rates of culturing, and distri-
bution of risk factors in these populations.
A number of studies have identified co-morbidities
most notably cancer and diabetes as risk factors for de-
velopment of Klebsiella species BSI [1, 14, 30–34]. How-
ever, with the exception of the population-based
investigation reported by Meatherall et al, these studies
have been within selected cohorts that are at significant
potential risk for bias. In their study from Calgary,
Meatherall et al found a number of determinants and
that solid organ transplantation, chronic liver disease,
dialysis, and cancer were the most important risk factors
for development of K. pneumoniae BSI [1]. We also ob-
served that renal disease and cancer were significant risk
factors for Klebsiella species BSI but notably we did not
find that liver disease significantly increased the risk.
While diabetes was found to be a significant risk factor
in both of our studies, after considering the high preva-
lence among controls in the population the magnitude
of this risk was relatively low compared to other co-
morbidities (Table 2). There are many reasons why ob-
served risk factors may be different in populations and
may be related to the specific populations under
Table 1 Co-morbid medical factors associated with risk for development of Klebsiella species bloodstream infection
Factor Estimated prevalence
in western interior
Cases Incidence with factor (per
100,000 population per year)
Incidence without factor (per
100,000 population per year)
IRR (95% CI) P-value
CVA (age 20+) 2.6% 16 81.1 13.9 5.9 (3.3–9.9) < 0.0001
Renal (age 20+) 3.1% 18 58.8 13.8 4.3 (2.5–7.0) < 0.0001
Cancer* 4% 45 36.1 9.4 3.8 (2.6–5.5) < 0.0001
CHF (age 20+) 2% 10 50.1 14.5 3.50 (1.6–6.6) 0.0012
Dementia (age 40+) 3% 12 57.5 19.9 2.9 (1.5–5.2) 0.002
Diabetes 9% 31 27.6 10.6 2.6 (1.7–3.9) < 0.0001
COPD (age 35+) 10% 30 39.2 16.8 2.3 (1.5–3.5) 0.0002
MI (age 20+) 8% 13 16.5 15.1 1.1 (0.6–1.9) 0.7
PVD (age 40+) 4% 3 10.1 20.1 0.5 (0.1–1.5) 0.2
Liver 10.0% 15 12.0 12.1 1.0 (0.5–1.7) 1.0
Peptic Ulcer 4.2% 10 24.1 14.8 1.6 (0.8–3.1) 0.2
Rheumatic Disease (age 20+) 2.9% 7 24.5 14.9 1.6 (0.6–3.5) 0.2
* Cancer includes solid tumors, leukemia, and lymphoma. Incidence rate ratio (IRR); cerebrovascular accident (CVA); congestive heart failure (CHF); chronic
obstructive pulmonary disease (COPD); myocardial infarction (MI); peripheral vascular disease (PVD)
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evaluation and the differences in study methodologies
and definitions.
While this study benefits from the population-based
design there are some limitations that merit discussion.
First, it is possible that we could have failed to ascertain
cases that occurred among residents of our region seek-
ing health care outside our region. Given that almost all
tertiary services are available in our area, we suspect that
this represents a small number but do not have actual
empiric data to justify this claim. Second, a diagnosis of
a BSI requires a positive blood culture and as such is re-
lated to the decision of clinicians to draw a specimen for
testing. This is a limitation inherent to all BSI studies.
Third, in establishing comorbid illnesses we did not have
individual patient level data on co-morbid illnesses on
residents of the region that did not develop BSI and
therefore had to estimate prevalence rates in our calcula-
tions. A degree of imprecision therefore exists in our de-
terminations and the magnitude of the risk factors
reported should be interpreted accordingly. Finally, be-
cause of the lack of individual co-morbidity data on con-
trols we were not able to determine independent risk
factors for acquisition using multivariable statistics.
Conclusion
In summary, our study documents the major burden of
Klebsiella species BSI in our region and is a significant
addition to the small number of previous population-
based studies conducted in other areas in Canada and
the United States. We further identify and confirm that
a number of co-morbidities are risk factors for these in-
fections. Further population-based studies conducted in
other regions outside of North America are warranted.
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